Phase 1/2, Multicenter, Non-randomized, Open-label, Multiple-Dose First-in-human Study of U3-1402, in Subjects with HER3 Positive Metastatic Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs U3 1402 (Primary)
- Indications Breast cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 23 May 2017 According to a Daiichi Sankyo Company media release, study design will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
- 02 Dec 2016 Status changed from not yet recruiting to recruiting.